{ Banner Image }
Search this blog

Subscribe for updates

Recent Posts

Blog editor

Blog Contributors

Showing 5 posts in PFAS.

On April 21, 2022, in Tomas Vera et al. v. Middlesex Water Co. (MID-L-6306-21, Superior Court of New Jersey, Middlesex County), a New Jersey Superior Court judge granted plaintiffs’ motion for certification in a case stemming from PFAS contamination of the county’s water supply.  Defendant Middlesex Water Co. (“Middlesex”) sent notices to customers on October 22, 2021 and November 8, 2021 advising that testing showed levels of Perfluorooctanoic Acid (“PFOA”) of 36.1 parts per trillion, well above the 14 parts per trillion maximum contaminant level (“MCL”) standard set by the New Jersey Department of Environmental Protection (“NJDEP”).  The notices further advised of health concerns potentially associated with PFOA, recommended that customers with “specific health concerns, a severely compromised immune system, have an infant, are pregnant or are elderly” seek advice from a health care provider, and recommended installing a home water filter to reduce levels of PFOA in the tap water or use bottled water for drinking, cooking, or preparing beverages for infants. Read More »

Recently, there has been an explosion of litigation involving per- and polyfluoroalkyl substances (“PFAS”) contamination.  In SUEZ Water New York Inc. v. E.I. du Pont de Nemours and Company, et al., No. 20-CV-10731 (LJL), 2022 WL 36489, at *1 (S.D.N.Y. Jan. 4, 2022), a federal district court dismissed PFAS related contamination claims against four Delaware corporate defendants:  E.I. du Pont de Nemours and Company, Inc. (“Old DuPont”), The Chemours Company (“Chemours”), DuPont de Nemours, Inc (“New DuPont”), and Corteva, Inc. (“Corteva”) (collectively “Defendants”).  The court dismissed the Complaint against New DuPont and Corteva due to lack of personal jurisdiction over each defendant.  Although the court found that personal jurisdiction existed over Old DuPont and Chemours, it ultimately still dismissed the Complaint against these defendants due to Plaintiff’s failure to state a claim against each of them. Read More »

In two recent decisions, courts have continued to preclude “classic” tort claims without proof of a current symptomatic condition and to place substantial limits on medical monitoring clams under state common law. In Benoit v. Saint-Gobain Performance Plastics Corporation, No. 17-3941 (2d Cir. 2020), the Second Circuit affirmed a district court’s denial of defendants’ motion to dismiss medical monitoring damages based on personal injury but cast significant doubt of the viability of such relief in the absence of any physical manifestation of exposure.  And in Letart v. Union Carbide Corporation, No. 2:19-cv-00877 (S.D. W.Va. 2020), the Court granted a motion to dismiss plaintiffs’ common law claims but allowed medical monitoring claims related to ethylene oxide (“EtO”) emissions to proceed, yet without addressing or determining whether the plaintiffs can meet the evidentiary requirements for such claims.  Read More »

On January 15, 2020, Judge Gerald J. Pappert of the Eastern District of Pennsylvania dismissed two groups of private plaintiffs’ claims against the United States Navy regarding perfluorocarbon contamination, PFOS and PFOA, in drinking water supplies around former Navy facilities in Bucks and Montgomery Counties, Pennsylvania. Giovanni v. U.S. Dept. of Navy, No. 16-4873, 17-765, -- F.Supp.3d --, 2020 WL 224683 (E.D. Pa. Jan. 15, 2020). Read More »

Earlier this month, the United States District Court for the Southern District of Ohio denied motions to dismiss filed by 3M Company, DuPont, Chemours, and other chemical companies in a putative class action lawsuit relating to exposure to PFAS chemicals. Hardwick v. 3M Company, Case No. 2:18-cv-1185 (S.D. Ohio). The court held that the named plaintiff had properly alleged an injury-in-fact for purposes of Article III standing and Ohio law by claiming that he was exposed to PFAS chemicals and that PFAS have been linked to negative health outcomes, despite arguments by the chemical companies that he had not suffered an actual, compensable injury.   Read More »